Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Cipla

Tracked across 12 events · 137 articles · First seen Mar 20, 2025 · Last active Sep 10, 2026

Sentiment
15
Attention
6
Events
12
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Cipla entered into an exclusive agreement with Pfizer India to market, distribute, and sell four of Pfizer's brands in India, expanding its presence in key therapy areas and leveraging its distribution capabilities.
Dec 19, 2025 · 6 articles
3 -30
Business
Impact: Cipla reported a 39% net profit decline due to North America sales drop and higher expenses; its India business achieved record sales. The company appointed a new CFO and expects sequential recovery in North America.
Jul 23, 2026 · 6 articles
4 -40
Regulatory
Impact: Cipla's Pune C&F unit lost its drug sale licences due to regulatory violations, leading to potential distribution disruptions and reputational damage. The company faces scrutiny over compliance practices, but the financial impact is expected to be manageable.
Aug 28, 2026 · 52 articles
4 20
Business
Impact: Cipla, through its subsidiary Invagen, is the licensee and commercializer of QL2107 in the US, strengthening its oncology biosimilar portfolio and potential future revenue.
Sep 03, 2026 · 6 articles
4 50
Business
Impact: Cipla received FDA approval for its generic Advair, positioning it as a direct competitor to Aurobindo in the US respiratory market.
Aug 31, 2026 · 7 articles
2 15
Tech
India's India — Drugs Controller General of India (DCGI) has approved an allogeneic bone marrow-derived mesenchymal stem cell therapy for knee osteoarthritis, marking the first time such an approved regenerative therapy enters clinical practice in…
Impact: Cipla is making the approved stem cell therapy available, positioning it as a distributor of a novel regenerative treatment in India. This could modestly enhance its specialty portfolio and reputation in advanced therapies.
Sep 10, 2026 · 6 articles
6 -30
Domestic
Impact: Cipla>>> is one of the generic drugmakers in India>>> that produces platinum-based chemotherapy, and its production is affected by the platinum shortage and price caps.
Jun 09, 2026 · 9 articles
2 50
Domestic
Impact: Cipla, a pharmaceutical company, was represented, indicating interest in India — Gujarat's pharmaceutical sector.
Sep 02, 2026 · 9 articles
4 20
Tech
Impact: Cipla is one of the 23 leading pharmaceutical companies included in the Indian Pharmaceutical Alliance, which is a partner in the Indian AI Research Organization (IAIRO) project.
Dec 30, 2025 · 7 articles
4 50
Regulatory
Impact: Achin Gupta, MD & Global CEO of Cipla, delivered the vote of thanks at the India Pharma 2026 conference.
Apr 12, 2026 · 6 articles
3 0
Regulatory
Impact: Cipla is mentioned only as former employer of Murali Neelakantan; not directly involved.
Jul 07, 2026 · 17 articles
0 0
Business
Impact: Cipla is mentioned as a client of IBSFINtech; no direct impact from the appointment.
Sep 03, 2026 · 6 articles
India ↔ Cipla
India ↔ Cipla
ERGEN INTELLIGENCE
Track Cipla live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.